Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to Surpass US$ 1,327.9 Million by 2027

Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, by Drug Class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 984.6 million in 2020 and is expected to exhibit a CAGR of 4.4% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing number of pipeline products of MRSA drugs Market is expected to drive the market growth over the forecast period. For instance, in 2018, Destiny Pharma received investigational new drug application from U.S. FDA for its new candidate, XF-73, a dicationic porphyrin molecule-based nasal gel to combat post-surgical infections of methicillin-resistant staphylococcus aureus (MRSA).

Methicillin-resistant staphylococcus aureus (MRSA) infection is an infection caused by antibiotic-resistant strains of the staphylococcus pathogen. Methicillin-resistant staphylococcus aureus (MRSA) is a bacterium that causes infections in different parts of the body. It is very difficult to treat most strains of staphylococcus aureus due to its resistant to some commonly used antibiotics but still it can be cured by certain antibiotics, which are used to kill or restrain methicillin-resistant staphylococcus aureus infection. Various antibacterial agents such as drug classes such as glycopeptides and lipoglycopeptides, oxazolidinones, lipopeptides, cephalosporin, and others can be used for the treatment of MRSA infection

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic has affected various industries globally. Supply of key materials has been severely disrupted due to the forced quarantine, and lack of labor and raw materials. As the link between regional warehouses is not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components have affected the supply chain of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the 2020. Moreover, due to the increasing prevalence of COVID-19, key players operating in the methicillin-resistant staphylococcus aureus (MRSA) drugs market are focusing on research and development of novel products to support and combat the effect of COVID-19. Ongoing clinical trials on antibiotic drugs such as Brilacidin is expected to show positive impact on the methicillin-resistant staphylococcus aureus drugs market growth.

Browse 26 Market Data Tables and 29 Figures spread through 206 Pages and in-depth TOC on “Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs”- Global Forecast to 2027, by Drug Class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-1538

Furthermore, product approvals and launches for the treatment of methicillin-resistant staphylococcus aureus (MRSA) are expected to boost the methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. For instance, in January 2018, Melinta Therapeutics, Inc. launched intravenous and oral formulations of Baxdela (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant staphylococcus aureus (MRSA).

Key Takeaways of the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market:

• The global methicillin-resistant staphylococcus aureus (MRSA) drugs is expected to exhibit a CAGR of 4.4% during the forecast period, owing to increasing approval & launches of novel drugs for the treatment of MRSA infections. For instance, in October 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) due to staphylococcus in adults.
• Among drug class, glycopeptides and lipoglycopeptides segment is estimated to hold a dominant position in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market in 2020, owing to frequent approval of new glycopeptide and lipoglycopeptide drugs by regulatory authorities in key regions. For instance, , in 2018, Cipher Pharmaceuticals Inc. received Health Canada approval for Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
• In terms of distribution channel, hospital pharmacies segment dominated the global methicillin-resistant staphylococcus aureus (MRSA) drugs market in 2019. High prevalence of asthma and MRSA in key regions such as North America and Europe is expected to increase hospital visits for its treatment, thereby driving growth of the hospital pharmacies segment.
• North America is estimated to hold largest market share in the global methicillin-resistant staphylococcus aureus (MRSA) drugs in 2020, owing to high healthcare awareness regarding therapeutics & advanced treatment optrions, favorable reimbursement scenario, increasing healthcare expenditure, and frequent approvals and launches of new drugs in the market.
• For instance, Centers for Disease Control and Prevention (CDC) and U.S. Department of Health and Human Services are working with healthcare facilities to meet the goals as per the 2013 National Action Plan to Prevent Healthcare-Associated Infections, and reduce bloodstream infections caused by MRSA by 50% by 2020 using the 2015 baseline.
• Key players operating in the global methicillin-resistant staphylococcus aureus (MRSA) drugs include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.